HomeCompareTGOPY vs HTGC

TGOPY vs HTGC: Dividend Comparison 2026

TGOPY yields 4.74% · HTGC yields 12.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TGOPY wins by $23.03M in total portfolio value· pulled ahead in Year 6
10 years
TGOPY
TGOPY
● Live price
4.74%
Share price
$8.09
Annual div
$0.38
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.75M
Annual income
$20,196,164.03
Full TGOPY calculator →
HTGC
Hercules Capital Inc.
● Live price
12.73%
Share price
$14.77
Annual div
$1.88
5Y div CAGR
32.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$718.3K
Annual income
$326,530.50
Full HTGC calculator →

Portfolio growth — TGOPY vs HTGC

📍 TGOPY pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTGOPYHTGC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TGOPY + HTGC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TGOPY pays
HTGC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TGOPY
Annual income on $10K today (after 15% tax)
$402.52/yr
After 10yr DRIP, annual income (after tax)
$17,166,739.43/yr
HTGC
Annual income on $10K today (after 15% tax)
$1,081.92/yr
After 10yr DRIP, annual income (after tax)
$277,550.93/yr
At 15% tax rate, TGOPY beats the other by $16,889,188.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TGOPY + HTGC for your $10,000?

TGOPY: 50%HTGC: 50%
100% HTGC50/50100% TGOPY
Portfolio after 10yr
$12.23M
Annual income
$10,261,347.27/yr
Blended yield
83.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HTGC right now

TGOPY
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Altman Z
6.2
Piotroski
6/9
HTGC
Analyst Ratings
17
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$18.81
+27.4% upside vs current
Range: $17.50 — $19.75
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TGOPY buys
0
HTGC buys
0
No recent congressional trades found for TGOPY or HTGC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTGOPYHTGC
Forward yield4.74%12.73%
Annual dividend / share$0.38$1.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR72.7%32.5%
Portfolio after 10y$23.75M$718.3K
Annual income after 10y$20,196,164.03$326,530.50
Total dividends collected$23.43M$623.4K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: TGOPY vs HTGC ($10,000, DRIP)

YearTGOPY PortfolioTGOPY Income/yrHTGC PortfolioHTGC Income/yrGap
1$11,518$817.82$12,667$1,686.53$1.1KHTGC
2$13,844$1,520.32$16,486$2,577.89$2.6KHTGC
3$17,763$2,949.49$22,150$4,048.82$4.4KHTGC
4$25,114$6,107.98$30,886$6,564.64$5.8KHTGC
5$40,811$13,938.38$44,958$11,045.93$4.1KHTGC
6← crossover$80,225$36,557.24$68,767$19,403.05+$11.5KTGOPY
7$201,829$115,988.69$111,321$35,814.23+$90.5KTGOPY
8$686,934$470,977.12$192,192$69,962.21+$494.7KTGOPY
9$3,322,277$2,587,257.59$356,787$145,759.66+$2.97MTGOPY
10$23,751,001$20,196,164.03$718,282$326,530.50+$23.03MTGOPY

TGOPY vs HTGC: Complete Analysis 2026

TGOPYStock

3i Group plc is a private equity firm specializing in mature companies, growth capital, middle markets, infrastructure, and management leveraged buyouts and buy-ins. The firm also provides infrastructure financing and debt management. For debt management, it invests in senior and mezzanine corporate debt in typically large and private companies in United Kingdom, Europe, Asia, and North America. It makes private equity investments in business and technology services, financial services, consumer, healthcare, consumption and distribution, media and telecom, renewable energy, wind, and industrial sector. Within business and technology services, the firm seeks to invest in sub sectors such as testing, inspection and certification; BPO and consultancy; human capital including staffing, governance, risk and compliance, services to pharmaceutical companies, vertical application software, education and training businesses; facilities management; support services to industrial sectors such as oil and gas and utilities; human resources outsourcing and advising; recruitment; logistics and infrastructure support services including distribution, waste, and rental. In the consumer sector, it focuses on polarization, health and wellness, ageing population, millennials, consumer goods; e-commerce; retail; food and drinks; and leisure. In the healthcare sector, the firm focuses on pharmaceuticals and biotechnology including specialty pharma, generics / OTC, drug delivery, and animal health; healthcare Services including activities such as elderly and specialty care, including caring for people in their own homes, in hospital and in community facilities, as well as operational services such as outsourced support, clinical services and B2B contract services; medical devices and technology including devices, medical equipment and consumables, diagnostics, and healthcare IT. In the industrial sector, it focuses on automotive, chemicals, construction and building products, electronics and electrical components, flow control and filtration, life science manufacturing, mobility, packaging, software, oil, gas and power. Through 3i BIFM Limited and 3i Infrastructure plc the firm makes infrastructure investments where it focuses principally on the utilities including energy transmission and storage, electricity and gas distribution, water, power generation, and communication network; transportation including airports, ports, ferries, toll roads, and rail; and social infrastructure sector including primary and secondary PFI, public private partnerships, healthcare, education, and government accommodation. In infrastructure it invests primarily in utilities, transportation and social infrastructure in the United Kingdom, France, Italy, Europe, and Ireland. The firm prefers to invest in companies across Europe, France, United States, South America, and Asia. It seeks to make new investments in Northern Europe and North America. The firm typically invests between €5 million ($5.59125 million) and €300 million ($335.475 million) in companies with an enterprise value typically between €100 million ($111.825 million) and €500 million ($559.125 million) and sales value between €80 million ($89.46 million) and €1500 million ($1677.38 million). It seeks to take either majority or minority stakes. It seeks to take a board seat in its portfolio companies with regards to infrastructure investments. The firm invests through a combination of third-party and proprietary capital. It invests through its personal capital. 3i Group plc was founded in 1945 and is based in London, United Kingdom with additional offices across Europe, North America, and Asia.

Full TGOPY Calculator →

HTGCBDC

Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. The firm prefers to invest between $10 million to $250 million in equity per transactions. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in December 2003 and is based in Palo Alto, California with additional offices in Connecticut; Boston, Massachusetts; San Diego, California; Westport, Connecticut; Elmhurst, Illinois; Santa Monica, California; McLean, Virginia; New York, New York; Radnor, Pennsylvania; and Washington, District of Columbia and London, United Kingdom.

Full HTGC Calculator →
📬

Get this TGOPY vs HTGC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TGOPY vs SCHDTGOPY vs JEPITGOPY vs OTGOPY vs KOTGOPY vs MAINTGOPY vs ARCCTGOPY vs GBDCTGOPY vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.